November 30, 2009 - Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE® with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE®.
The details can be read here.
No comments:
Post a Comment